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Pulmonary function in patients with trophoblastic
disease treated with low-dose methotrexate
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Summary The Sheffield Trophoblastic Disease Centre treats about 25 patients with persistent trophoblastic disease each year. A total of
75% of patients are classified as low risk according to the Charing Cross Hospital prognostic scoring system and receive methotrexate (MTX)
50 mg, i.m., on days 1, 3, 5, 7 with folinic acid 7.5 mg orally 24 h after each methotrexate injection. There is a 7-day rest between treatment
cycles. Remission is achieved in 85% of cases. Approximately 20% of patients experienced pleuritic chest pain and dyspnoea. We have
evaluated prospectively lung function in 16 low-risk patients receiving methotrexate. All patients had pulmonary function tests [spirometry-
forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), peak expiratory flow rate (PEFR), and transfer factor - TLCO, kCO]
performed before and after completed treatment. A mean of 7.5 cycles of MTX were administered (range 4-11). There was a significant
reduction in the mean TLCO (mean pre/post 8.15/7.38 mmol min-' kPa-1, P = 0.01), but there were no other statistically significant changes.
Three patients experienced respiratory symptoms and were found to have a 39%, 28%, and 11% reduction in TLCO from baseline, improving
on follow up to pretreatment levels. Low-dose MTX is an effective therapy but may cause troublesome pulmonary toxicity.
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In 1973 the Royal College of Obstetricians and Gynaecologists
and the Department of Health initiated the UK trophoblastic
disease registration scheme. Supraregional centres to coordinate
the scheme were established at Charing Cross Hospital, London,
Jessop Hospital for Women, Sheffield, and Ninewells Hospital,
Dundee. The Sheffield centre was subsequently relocated to
Weston Park Hospital under the aegis of the University
Department ofClinical Oncology.
In Sheffield there are around 400 registrations per year of
women with gestational trophoblastic disease. Approximately
5-6% ofthese registrations (around 25 patients each year) require
chemotherapy. The small proportion of patients requiring treat-
ment reflects the stringent treatment criteria adopted at our centre
(Sheridan et al, 1993). In the United States, some 20% ofpatients
developing molar pregnancies can expect to receive chemotherapy
(Goldstein and Berkowitz, 1982; Lurain et al, 1983).
The need for treatment is identified by the establishment offirm
evidence of persistent disease activity unlikely to resolve sponta-
neously. Such patients are reviewed at the treatment centre and
staged according to a modified Charing Cross Hospital Prognostic
Scoring system (Bagshawe, 1976; Sheridan et al, 1993). In
Sheffield, patients are classified according to their prognostic
score as low (< 7) orhigh risk (> 7).
Approximately 75-80% ofour patients requiring chemotherapy
are in the low-risk treatment category - they receive a low-dose
methotrexate regimen. Methotrexate treatment achieves remission
and cure in 80% of cases, with the remaining patients requiring
salvage chemotherapy (actinomycin and etoposide).
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The low-dose methotrexate regimen is usually well tolerated.
The most common side-effects of treatment are conjunctivitis and
oral mucositis, which are usually ameliorated with appropriate
therapy. However, approximately 20% of patients (Sheridan et al,
1993) experience the potentially disabling side-effects ofpleuritic
chest pain and dyspnoea. If severe, this can lead to the discontinu-
ation of methotrexate therapy and alteration of treatment to other
chemotherapeutic agents.
In a number of conditions, pulmonary toxicity with the clinical
and pathological features ofpneumonitis has been described after
methotrexate administration (Sostman et al, 1976). However, the
association between pleurisy and pulmonary function has not been
previously investigated. The objective of this study was to
prospectively assess pulmonary function inpatients with persistent
trophoblastic disease treated with single-agent methotrexate.
MATERIALS AND METHODS
Subjects
This report describes our findings in 16 consecutive patients with
low-risk persistent trophoblastic disease who required treatment
with methotrexate between February 1994 and August 1995. The
median age of the group was 25.5 years (range 15-35), median
risk score 4 (range 2-6) and median number oftreatment cycles 8
(range 4-11).
Only 2 out of the 16 patients had pulmonary metastases
detectable by chest computerized tomography (CT) scan.
Treatment
The low-dose methotrexate regimen consists of methotrexate
50 mg, i.m., administered on days 1, 3, 5 and 7 with folinic acid
7.5 mg orally 24 h after each methotrexate injection. There is a
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Table 1 Pulmonary function analysis before and after methotrexate treatment (n = 16)
Before treatment After treatment
Mean Standard error of Mean Standard error of
Test Units mean mean P-value
PEFR min-' 469 24.4 471 26.6 0.89
FEV, 3.36 0.14 3.35 0.14 0.93
FVC 4.08 0.18 4.11 0.19 0.76
TLco mmol min-' kPa-1 8.15 0.28 7.38 0.33 0.01
kCO mmol min-' kPa-'I-l 1.65 0.05 1.55 0.07 0.30
Alveolar volume 4.98 0.20 4.81 0.20 0.27
Haemoglobin g dl-1 12.1 0.36 11.65 0.22 0.10
*Significant.
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Figure 1 kCO before and after methotrexate treatment. - - -, symptomatic
patients; -, asymptomatic patients
7-day rest between treatment cycles. Serum beta human chorionic
gonadotrophin (3hCG) levels are monitored closely during the
treatment and should fall rapidly. Suboptimal falls or persistently
elevated ,hCG indicate drug-resistant disease, necessitating alter-
ation of chemotherapy. The level of PhCG may become normal
2.20 when there is still a residual tumour burden
Therefore, treatment is continued for 8 weeks
remission.
2.10
Pulmonary function tests
of 105-106 cells.
after biochemical
Pulmonary function analysis was performed in each subject before
commencement of the first treatment cycle and at the conclusion
of the last cycle. The technicians performed the tests in a single-
blind fashion, being unaware of the patient's condition or treat-
ment. Those patients who experienced respiratory symptoms
during treatment were recalled for follow-up analysis. The
following pulmonary function tests were used in the assessment:
(a) Forced expiratory volume in 1 (FEVy), forced vital
capacity (FVC) and peak expiratory flow rate (PEFR) were
measured by spirometer (Vitalograph Compact).
(b) Single breath transfer factor (TLCO) was measured on the
Gould Diffumatic.
The transfer factor is a measure of gas transfer from the alveoli to
the blood in the pulmonary capillaries. Transfer is measured for the
whole lungs - 7nCO, and thecoefficient perunit ofalveolar volume
(kCO) can be calculated. The transfer factorhas become established
as a sensitive and reproducible routine pulmonary function test.
In our laboratory, standard methods are adopted for measuring
transfer factor (Guidelines for the Measurement of Respiratory
Function, 1994). The coefficient of variation for the test is
approximately 5% - although this is reduced in our laboratory
by repeating the test and reporting the mean value.
Statistical analysis
All pulmonary function tests yield biological datathatarenormally
distributed. As the number ofobservations in our study is relatively
small, paired t-tests for means with the appropriate degrees of
freedom have been used for statistical analysis ofthe data.
RESULTS
Table 1 shows the results for the 16 subjects in the group as a
whole. It can be seen that there is no significant change in PEFR,
FEVy, FVC, kCO, alveolar volume or haemoglobin. There is,
however, a significant reduction in transfer factor (TLCO)
from a mean of 8.15 mmol min-' kPa-' before treatment to
7.38 mmol min-' kPa-1 after treatment (P = 0.01).
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pain during the second, third and fourth treatment cycles. Her
chemotherapy was therefore altered to an oral etoposide regimen.
The patient experienced no further respiratory problems and
completed treatment 2 months after biochemical remission. (A
treatment summary is shown in Figure 2.)
Chemotherapy
Symptoms
x x x x x x x x
1 2 3 4 5 6 7 8 9 10 11 12
Time (weeks)
Methotrexate
Etoposide
Figure 2 Case 1 treatment summary
Table 2 Observations in symptomatic patients
Test Before After Follow-up
treatment treatment
Case 1 TLCO 7.4 5.3 (-28%) 7.8
kCO 1.83 1.07 (-32%) 1.42
Va 4.04 4.95 (+ 23%) 5.49
Hb 11.0 12.0 (-8%) -
Case 2 TLco 9.3 8.3 (- 11%) 9.8
kCO 1.85 1.43 (-23%) 1.60
V. 5.02 5.80 (+ 16%) 6.13
Hb 11.6 12.1 (+4%) -
Case 3 TLCO 9.4 5.7 (- 39%) 8.1
kCO 1.86 1.14 (-39%) 1.62
Va 5.05 5.00 (-1%) 5.00
Hb 8.8 10.7 (+ 22%) -
Units: TLCO, mmol min-' kPa-'; kCO mmol min-' kPa-' I-'; alveolar volume
(Va), l; haemoglobin (Hb), g dl-'. Case 3, blood transfusion following
commencement of therapy. Follow-up in months following conclusion of
treatment: case 1, 24; case 2, 16; case 3, 15.
By studying the group as a whole, it is impossible to analyse the
effects oftreatment on individual patients - and it is these data that
may prove to be far more relevant. Figure 1 shows pre- and post-
treatment kCO values for all subjects studied. The effect of treat-
ment is varied, with some patients having an increase and others a
decrease in kCO. It is, however, of note that the three patients
experiencing the largest falls in kCO were those who developed
respiratory symptoms during treatment, suggesting that such
patients may have measurable lung function impairment. These
cases are described below.
Case 1
A 23-year-old woman with persistent trophoblastic disease was
referred for assessment in February 1994. Despite two attempts to
evacuate her uterus, she had persistent bleeding per vaginum
and an elevated 3hCG. Staging investigations were performed;
the patient had a risk score of 4 and was started on the low-
dose methotrexate regimen. The patient achieved biochemical
remission by the commencement ofthe third cycle - however, she
Case 2
After the diagnosis of a molar pregnancy, this 28-year-old patient
had three attempted uterine evacuations. However, her f-hCG
remained persistently elevated and she was assessed here in
November 1994. The patient had a Charing Cross risk score of 4
and was therefore treated with methotrexate. After two courses the
patient was in biochemical remission and went on to complete five
cycles of therapy. However, during the fourth and final cycles she
experienced severe dyspnoea and pleuritic chest pain. The patient
experienced no further respiratory symptoms after the conclusion
of treatment.
Case 3
An 18-year-old woman presented to her local gynaecologist with
bleeding per vaginum in early pregnancy. After a pelvic ultrasound
scan, a diagnosis of suspected molar pregnancy was made and the
patient underwent a suction curettage. Histological analysis of the
products of conception confirmed the diagnosis. Despite a further
uterine evacuation, the patient's bleeding persisted and ,BhCG
remained elevated. On review at the treatment centre, in December
1994, the patient had a risk score of 4 and was commenced on
methotrexate. The patient had a haemoglobin count of 8 g dl-I and
required abloodtransfusionduringherfirstcycleoftreatment. After
three cycles the patient was in biochemical remission and treatment
was concluded after seven cycles. During the fourth and fifth cycles
she experienced pleuritic chest pain and dyspnoea. Simple analgesia
was used prophylactically in subsequent cycles to good effect.
None ofthe three patients had chest metastasis detectable on CT
scans before commencing chemotherapy. All had numerous inves-
tigations performed when they experienced theirrespiratory symp-
toms. Of note, no infectious agents were identified on sputum
culture and there were no abnormal findings on electrocardiogram
or chest radiograph. A ventilation-perfusion scan was performed
on patient number 2 and no abnormality was detected. Simple
analgesia was used to provide pain relief - opiates being used in
case 1 only when this provided inadequate symptom relief.
Table 2 shows the percentage changes in TLCO and kCO experi-
enced by these three symptomatic patients. No significant changes
were seen in any other parameter measured.
At the conclusion of the study we recalled these patients and
again performed pulmonary function analysis. As shown in Table
2, in all patients the TLCO and kCO changes have resolved or
appear to be returning to baseline.
DISCUSSION
Methotrexate is a commonly used chemotherapeutic agent. In
addition to its use in a wide variety of neoplastic conditions, it is
also used to treat severe unresponsive psoriasis and other severe
immunologically mediated disease states. In a number of these
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conditions, pulmonary complications have been described
following methotrexate administration (Sostman et al, 1976).
The dosage of methotrexate received by a patient is dependent
on the condition being treated. Pneumonitis is experienced by
those receiving both high and low doses - indeed some earlier
investigators found the complication more common in those
receiving small oral doses (Clarysse et al, 1969). A conclusion was
drawn that the route of administration was the dependent factor
(Zurek et al, 1968). This, however, was not supported by subse-
quent studies (Nesbit et al, 1976), and pharmacological data
suggest that this particular complication is a schedule-related, not
dose- or route-related, phenomenon (Louis et al, 1970; Huffman et
al, 1973). This may explain the high incidence of methotrexate-
induced pneumonitis in our patients, in whom low doses of the
drug were administered relatively frequently.
The pathogenesis of methotrexate-induced pneumonitis is not
fully understood. Previous investigators have performed lung
biopsies in symptomatic patients, histological analysis being typi-
fied by alveolar damage, interstitial inflammation, alveolar space
infiltrates and hyaline membrane formation (Sostman et al, 1976).
Others suggest thatthis condition is the resultofan immunological
cell-mediated mechanism (Akoun et al, 1987; White et al, 1989),
although clinical data suggest that repeat exposure to methotrexate
seldom leads to a worsening of the pneumonitis (Sostman et al,
1976; Willson, 1978).
It has previously been shown that the transfer factor may alter
with methotrexate-induced pneumonitis (Arnett et al, 1973). Our
results show that transfer factor is significantly reduced in a cohort
of patients receiving methotrexate for persistent trophoblastic
disease. It should be noted, however, that this alteration of lung
function in our study group is heavily influenced by the results in
our symptomatic patients, and if all observations recorded by
these patients are removed from the statistical analysis there is no
significant change in any parameter.
The transfer factor (7LCO) is a measure ofgas transfer from the
alveoli to the blood in the pulmonary capillaries. In human lungs
the diffusion pathway consists of the alveolar space, alveolar
epithelium, alveolar basement membrane, tissue space, capillary
basement membrane, capillary endothelium, capillary lumen and
the erythrocyte. The transfer of oxygen is by means of simple
diffusion. It is influenced by the surface area over which transfer
takes place, the length and permeability of the diffusion pathway,
the partial pressure gradient of oxygen and the rate of oxygen
uptake by haemoglobin in the erythrocyte. Predicted values are
standardized for age, height and sex.
Dividing TLCO by alveolar volume gives the coefficient of
transfer (kCO). This assesses if a reduced transfer factor is caused
by a diminished alveolar volume with a normal diffusion pathway
or a normal alveolar volume with an impaired diffusion pathway.
Figure 1 shows the alteration ofkCO with methotrexate treatment
in our study group. The effect of treatment on the kCO is not
consistent; however, large falls were demonstrated in the three
symptomatic patients. These patients (and some others to a lesser
degree) have apparently undergone a methotrexate-induced deteri-
oration in diffusion pathway function. One could postulate that the
critical level of loss of function is required for the patients to
experience symptoms. In our study, we did not perform broncho-
alveolar lavage or lung biopsy on any patients. It is not, therefore,
possible to state definitely the pathological process responsible for
the falls in kCO. However, either an immune alveolitis or an
inflammatory infiltrate into the tissue space would result in an
impairment of diffusion pathway function - and so could explain
our findings. The effect on function would appear to be temporary,
as all symptomatic patients have kCO values that revert towards
baseline at long-term follow-up.
The treatment of methotrexate-induced pneumonitis can be
difficult - in some cases it leads to the alteration of the chemo-
therapeutic regimen despiie adequate tumour response. There is
anecdotal evidence that adequate hydration and increasing the
dosage of folinic acid rescue may reduce the incidence of this
complication. For those who develop pleurisy, simple parac-
etamol-containing analgesia may provide adequate symptomatic
relief; if not, the use of tramodol hydrochloride may reduce the
need to resort to conventional opiate analgesia. Non-steroidal anti-
inflammatory drugs are not recommended as they reduce renal
methotrexate excretion. Therole ofcorticosteroids in the treatment
ofthis complication is unproven.
In conclusion, methotrexate is a highly effective first-line
chemotherapeutic agent for treatment of low-risk persistent
trophoblastic disease. It is the drug of choice because of its effi-
cacy and relative lack of short- and long-term toxicity (Bagshawe
et al, 1989). Unlike other agents active in the treatment of this
disease, methotrexate has not, so far, been associated with sub-
fertility or second tumour induction (Rustin et al, 1987, 1996).
Treatment with low-dose methotrexate is usually well tolerated;
however, up to 20% of patients will experience methotrexate-
induced pulmonary toxicity. This study shows that such toxicity
can be associated with significant, though temporary, changes in
pulmonary function. Consideration should be given to altering
therapy in patients who develop respiratory problems and/or show
a deterioration in,pulmonary function. Low-dose methotrexate is
not an innocuous treatment, however, it should still be regarded as
standard treatment for patients with persistent low-risk gestational
trophoblastic disease.
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